CCA
PFE icon

Cygnus Capital Advisors’s Pfizer PFE Stock Holding History

Cygnus Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.01K Buy
142,800
+2,700
+2% +$71.9K 2.74% 8
2025
Q4 		$3.49K Buy
+140,100
New +$3.53M 2.55% 6

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Cygnus Capital Advisors's PFE Position: Q1 2026 in Review

Cygnus Capital Advisors increased its Pfizer (PFE) stake by 1.9% in Q1 2026, buying an estimated $71.9K and bringing the position to 142,800 shares worth $4.01K. The position accounts for 2.74% of the portfolio, ranked #8.

Cygnus Capital Advisors first reported a position in PFE in Q4 2025 and has held it in 2 quarters since. 2,952 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Cygnus Capital Advisors held 142,800 shares of Pfizer worth $4.01K as of Q1 2026.
  • Cygnus Capital Advisors bought 2,700 Pfizer shares in Q1 2026, an estimated $71.9K.
  • Pfizer made up 2.74% of Cygnus Capital Advisors's portfolio in Q1 2026, its #8 holding.
  • Cygnus Capital Advisors first reported a position in Pfizer in Q4 2025 and has held it in 2 quarters since.
  • 2,952 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.